|
|
Galmed Pharmaceuticals Ltd (GLMD) |
|
|
|
Galmed Pharmaceuticals Ltd 's Yearly Income from Continued Operations Growth 5 Years |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
GLMD Annual Income from Cont. Operations Growth |
2022
|
2021
|
2020
|
2019
|
2018
|
Y / Y Annual Income from Cont. Operations Change |
-44.97 % |
12.85 % |
40.61 % |
107.6 % |
-19.86 % |
Annual Income from Cont. Operations (in millions $) |
$17.87 |
$32.47 |
$28.77 |
$20.46 |
$9.86 |
Annual Income from Cont. Operations Growth
Comment |
Galmed Pharmaceuticals Ltd experienced detoriation of Annual Income from Cont. Operations for the fiscal year ended 2022 by -44.97% to $ 17.87 millions, compare to $ 32.47 in Annual Income from Cont. Operations reported in the previous year. The decline in company's annual Income from Continued Operations accelerated, from the 12.85 % gain, in the fiscal year ended 2021.
Galmed Pharmaceuticals Ltd Annual Income Statement
|
You need to upgrade your Flash Player
|
Companies with similar 2022 Annual Income from Cont. Operations within Healthcare Sector | Y/Y Income from Continued Operations Growth % | 2022 Annual Income from Cont. Operations | Sinovac Biotech Ltd | -99.39 % | $ 88.131 millions | Fulgent Genetics Inc | -71.97 % | $ 141.923 millions | Uniqure N v | | | |